gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin play support agtc thesi
highlight week septemb septemb unrat announc respons
interest initi process explor strateg altern includ partner variou clinic pre-
clinic program sale merger compani share trade news note certain
similar anoth aav-bas gene therapi gt compani agtc recent upgrad buy agtc
compani dramat high trade cash scienc larger player lack medicin
compani buy chardan top pick present full result european societi cardiolog esc
phase trial rnai therapeut inclisiran addit ldl-c lower good
safeti inclisiran earli signal potenti cv outcom benefit import new posit regenxbio
buy chardan top pick announc world-wide option licens agreement clearsid biomed
unrat use clearsid microinjector deliveri anti-vegf gt view
news posit due potenti microinjector preserv advantag
subretin inject avoid disadvantag avoid disadvantag intravitr ivt
inject uniqur buy chardan top pick announc plan enrol achiev
hope-b pivot phase trial gt addit patient enrol
respons interest patient studi investig continu believ hope-b trial result
expect like posit uniqur leadership hemophilia gt space
look forward septemb septemb septemb veeva summit take place
philadelphia agenda includ amicu therapeut neutral biomarin unrat
buy novarti unrat buy septemb intern congress porphyrin
porphyria held milan agenda includ buy septemb car-
tcr summit held boston agenda includ adaptimmun unrat unrat
therapeut privat precis bioscienc unrat other septemb retina societi
meet held london agenda includ adverum biotechnolog neutral agtc buy
unrat hemera bioscienc privat neutral adverum addit host
confer call septemb discuss data optic phase trial
base gt wet septemb heart failur societi america meet held
philadelphia agenda includ akcea therapeut unrat unrat follow
compani host day buy septemb new york citi silenc therapeut
unrat septemb new york citi iver neutral septemb new york citi
weekli price move vivo genet medicin aav srna mrna vivo gene edit
upcom chardan genet medicin event contact chardan rsvp
bold buy pt increas model asset clinic septemb amusa
audent therapeut updat model includ risk-adjust estim pomp diseas duchenn
muscular dystrophi dmd reiter buy rate dcf-deriv contribut
 xlmtm npv/share
pleas refer import disclosur inform regul analyst certif found page report
 pomp diseas npv/share
 dmd npv/share
agtc upgrad buy below-cash play option xlrp septemb amusa
upgrad agtc buy opportun repres compani trade march cash
import phase i/ii data program xlrp
think posit result merit agtc trade price target failur
program us would limit downsid given agtc could becom revers merger candid privat
compani want go public could acquir number public compani
mdco buy import hint cv benefit inclisiran septemb amusa
medicin compani chardan top pick announc full result pivot phase trial
show ldl-c lower good safeti inclisiran
believ result cv endpoint myocardi infarct stroke posit earli signal
expect cv outcom benefit phase trial
uniqur chardan top pick announc phase hope-b trial rnai therapeut
inclisiran achiev enrol would enrol addit patient
expect result hope-b trial due suggest market leadership uniqur hemophilia gt
buy precis deliveri deal septemb amusa
announc exclus world-wide licens option agreement clearsid biomed unrat
view microinjector technolog net posit given
includ use clearsid microinjector deliveri gt
 preserv advantag subretin inject name better transgen express retina
 avoid disadvantag name need procedur
 limit prevent key disadvantag ivt name exposur vitreou anterior segment
eye gt may caus inflamm neuron death
genet medicin news septemb septemb
harvard publish crispr base editor reduc off-target activ septemb
rhhbi six unrat announc extens tender offer spark tx neutral septemb
unrat announc strateg review explor possibl partner sale septemb
unrat announc odd rpdd aso tx angelman septemb
dynacur privat announc appoint david garrett cfo septemb
unrat announc acquisit type diabetes-focus semma tx privat septemb
buy present biomark studi uk biobank cohort analysi eu-attr septemb
gyroscop tx privat announc mm seri rais surgic deliveri septemb
unrat announc ind clearanc allogen ipsc-deriv nk cell tx septemb
autl unrat announc public natur medicin technolog septemb
dvm neutral report vice-president gener counsel dr jennif cheng step septemb
gnpx unrat provid mileston guidanc busi updat septemb
unrat announc plan us trial ex vivo lentiviru gt fa septemb
ortx unrat announc updat pi/ii trial ex vivo lenti gt mp septemb
ortx unrat announc result relat ex vivo lentiviru gt mld septemb
page
orchard present collabor sr-tiget societi studi inborn error
metabol ssiem integr data analysi phase i/ii trial expand access
program ex vivo lentivir gt
orchard report statist signific differ gross motor function measur observ
treat patient untreat age-match particip natur histori cohort
orchard report comparison gross motor function two age-match group show signific
differ late infantil patient untreat age-match natur histori cohort
percentag point follow-up respect
orchard also note gross motor function differ persist earli juvenil patient report
signific differ untreat age-match natur histori cohort percentag point
percentag point follow-up respect
cyad unrat announc updat car-t tx manufactur optimab septemb
oxb gb unrat announc financi result provid busi updat septemb
unrat announc data pi/ii studi gt gsdia septemb
ultragenyx announc posit data cohort phase i/ii trial investig safeti
toler respons gt adult gsdia
result cohort announc februari show singl dose gc/kg led sustain
improv time hypoglycemia patient seriou advers event ultragenyx report
patient demonstr biolog clinic respons reflect increas time hypoglycemia defin
glucos mg/dl onset clinic symptom compar baselin controlled-fast challeng
notabl patient cohort exhibit signific hyperglycemia control fast challeng
observ baselin cohort although compani report hyperglycemia consist
increas transgen express glucos releas due dose escal may interpret neg
exampl level hyperglycemia lead exagger insulin respons could drive hypoglycemia
ultragenyx proceed confirmatori expans cohort dose gc/kg event
posit clinic data phase trial expect initi
selb unrat announc appoint brad dahm cfo septemb
tx privat announc appoint terry-ann burrel cfo septemb
buy initi pi/ii studi gt arci septemb
passag privat announc mm seri financ gt program septemb
nkarta tx privat announc mm seri financ support nk cell therapi septemb
qure buy announc price public stock offer mm septemb
unrat announc appoint independ board member septemb
unrat announc dose first patient ex vivo gt lad-i septemb
buy announc public molecular biolog dystrophin protein septemb
ly fp unrat provid updat overview clinic trial program septemb
lysogen announc complet natur histori studi mucopolysaccharidosi type
iiia mpsiiia data collect pool previous publish data serv control arm on-going
lysogen also announc launch provid innov approach record measur treatment effect
post gene therapi phase studi approach meant provid video document patient progress
serv adjunct gt registr commerci posit
compani mention report
page
page
select catalyst genet medicin coverag
dose patient phase studi mp
provid updat phase i/ii studi hemophilia
aro-aat initi phase ii/iii studi liver diseas
lumasiran initi illuminate-c phase trial
file ind pomp diseas
inclisiran report top-line data orion studi hypercholesterolemia
initi phase i/ii clinic trial huntington diseas
initi phase ii trial /- cemiplimab cutan squamou cell carcinoma
initi phase trial /- solid tumor
initi phase i/ii trial dmd nationwid children hospit
report interim efficaci readout phase oval trial ovarian cancer
report dose escal data pi/ii trial achm/xlrp
dcr-hbv anticip first interim data clinic trial hbv
provid initi data phase trial gangliosidosi
provid initi data phase trial gangliosidosi
axo-lenti-pd report data cohort sunrise-pd phase ii trial
submit ind methylmalon acidemia mma
present data phase portion solid tumor trial /- nivolumab
provid earli data cohort phase i/ii pioneer trial n- rp
file ind phase ii studi diabet retinopathi dr
present interim data pi/ii studi mp ii pi studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
file ind batten diseas
top-lin phase ii data treat deb patient chronic wound
initi dose phase trial hemophilia
provid updat priorit program sjogren syndrom al wet
initi patient dose brillianc phase i/ii trial
report result phase i/ii ignit dmd trial
initi phase iib studi wet
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
file ind huntington diseas program
 fc initi phase ii/iii trial newli diagnos glioblastoma
 fc safeti activ readout phase ib trial met solid tumor
present preclin data new gt program fabri pomp defici
provid follow-up data piib dose-confirm studi hemb
file ind cta pomp diseas
present top-lin data phase i/iia clinic trial wet
 fc report final analysi phase trial rhgg
declar develop candid aml
initi phase trial dystroph epidermolysi bullosa deb
figur alnylam/mdco meiragtx replimun solid uniqur expect import data read-out
page
select catalyst outsid genet medicin coverag
nsr-rpgr provid prelim data expans cohort phase ii/iii trial xlrp
dtx provid phase i/ii cohort data ornithin transcarbamylas defici
zolgensma anticip approv eu
nsr-rpgr report follow-up data open label dose escal phase xiriu studi
valrox submit bla pend fda feedback hemophilia
initi pivot phase trial rdeb
initi phase data patient leukocyt adhes deficiency-i lad-i
report initi phase data process fanconi anemia
suvodirsen interim data open-label extens studi dmd
initi phase studi pyruv kinas defici pkd
initi us phase ii studi fanconi anemia
initi phase i/ii trial parkinson diseas mutat
begin dose patient investigator-sponsor phase i/ii trial cystinosi
initi phase i/ii trial type gaucher diseas
bmn file ind phenylketonuria pku
initi phase ib trial beta-thalassemia
initi phase trial multipl myeloma
initi clinic trial charcot-marie-tooth type
file approv transit clinic trial platform manufactur
micro-dystrophin initi pivot trial duchenn muscular dystrophi
initi phase ii studi overact bladder
initi phase i/ii trial gangliosidosi
zolgensma complet strong phase trial pre-symptomat sma type
initi phase i/ii studi best diseas
micro-dystrophin initi confirmatori trial commerci materi dmd
begin patient dose phase trial
nsr-rpgr provid follow-up data phase xiriu dose escal studi xlrp
file ind inherit amyotroph later sclerosi
tegsedi expect approv brazil hattr amyloidosi
 anticip data readout phase trial hd
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
ptc-fa file ind friedreich ataxia fa enter clinic
sea-bcma report preliminari phase dose escal data r/r mm
lentiglobin initi phase studi sickl cell diseas
zynteglo initi roll bla submiss fda tdt
report initi data phase i/ii trial phenylketonuria pku
rituximab report preliminari phase cohort data r/r nhl
figur plan file bla aadc defici
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma fibrocel buy lysogen oncosec medic oxford biomedica buy vbl neutral
figur select price movement week end sep vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm abeona genet therapytickerratingccm ptupsideclosechang changemc mm arbutu gene editingtickerratingccm ptupsideclosechang changemc mm logicbio pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note though avx nite acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap pharmaceut
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
 targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid technolog
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti ntech curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani pharmaceut
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan recombinet technolog pharmaceut
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
swedish orphan biovitrum astrazeneca
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
price prv
page
date fda rpdd
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
ultragenyx genetx
page
date fda ftd
crispr vertex
crispr vertex
parkinson diseas mutat
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genetx ultragenyx
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
parkinson diseas mutat
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
